Ondine Biomedical Inc., a frontrunner in light-activated antimicrobial technology to counter and manage hospital infections, draws attention to its robust operational achievements in H1 2024, revealing substantial strides and development in both its commercial and clinical initiatives.
Dominating the first half of 2024, this dynamic enterprise recorded an influx in the adoption of its revolutionary Steriwave® light-activated antimicrobial – boasting adoption in 29 hospitals, marking a remarkable 190% enhancement compared to the prior year. Shining a light on the company’s financial triumph, Ondine has successfully clinched a lucrative $0.9 million in revenue, indicating a monumental 101% increase from H1 2023.
This upsurge was achieved while maintaining consistent operating costs, intelligently neutralizing increased expenditures related to Phase 3 clinical trial preparations through calculated cost-saving measures. Benefitting from the advantageous partnership with Mölnlycke Health Care, this has set in motion exceptional advancements in accelerating adoption of Steriwave in key markets.
The noteworthy progress observed in H1 2024 now positions Ondine ideally for a captivating second half of the year, filled with ripened opportunities and vast potential as it continues to push the envelope in antimicrobial technology and infection prevention.
Central to this success is the tenacious CEO, Carolyn Cross, who shone by not only leading the company to such operational and financial victories, but also by providing crucial financial support on a no interest, unsecured basis, thus bolstering the backbone of this thriving company.
Source: https://www.accesswire.com/925367/ondine-biomedical-reports-robust-growth-in-h1-2024